SGRY$15.5
Chart
Performance
Key Stats
AI SGRY Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldA company with solid thematic positioning in healthcare services but mixed fundamental metrics and neutral to weak technical signals. Suitable for cautious investors with a focus on long-term recovery and stabilization.
Thematic
Surgery Partners operates a diversified network of surgical and ancillary healthcare services in the U.S., well-positioned in the ambulatory and specialty surgery space amid aging population trends and increasing outpatient procedures.
Fundamental
The company shows challenges in profitability and valuation metrics with high debt levels and negative earnings, offset somewhat by improving free cash flow and stable revenue growth.
Technical
The stock exhibits mixed technical indicators with slight bearish momentum in the short term but stable longer-term trends suggested by moving averages and oscillators.
| Factor | Score |
|---|---|
| Healthcare Services Network | 75 |
| Demographic Tailwind | 72 |
| Regulatory Environment | 60 |
| Innovation Adoption | 70 |
| ESG & Sustainability | 63 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 40 |
| Growth | 55 |
| Balance Sheet Health | 35 |
| Cash Flow | 65 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 50 |
| Volume Confirmation | 45 |
| Support & Resistance | 55 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Improving Quarterly Earnings Surprises
Recent quarterly earnings surprises have shown positive beats such as Q1 2025 (+17.26%) and Q3 2024 (+5.05%), indicating improving earnings performance despite past volatility.
Reasonable Price-to-Sales Ratio
The company's trailing 12-month Price-to-Sales ratio of 1.2 is moderate, suggesting the stock is not excessively overvalued relative to its sales compared to sector averages.
Bearish Points (5)
Negative Earnings and EPS Volatility
EPS remains negative (TTM EPS: -1.53), and net income is negative for multiple recent periods, signaling ongoing profitability challenges.
Negative P/E Ratio and Declining Profit Margins
Price-to-Earnings ratios are negative (around -16 to -243 historically), reflecting net losses and raising valuation concerns given weak profitability and shrinking net margins (-5.4% recent).
Calendar
August 2025
4
Next Earnings Date
H: $0.24
A: $0.14
L: $0.01
H: 830.00M
A: 816.96M
L: 785.00M
Profile
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; and ancillary services, such as multi-specialty physician practices, urgent care facilities, and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
Seasonals
Price Target
31.36 USD
The 39 analysts offering 1 year price forecasts for SGRY have a max estimate of 36.00 and a min estimate of 24.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Biotechnology company with similar drug development focus and market segment as Sangroy Inc. (SGRY)
Weight: 95
Leading biotech company specializing in neurodegenerative diseases and biologics, closely related in R&D pipeline.
Weight: 93
Biopharmaceutical company focusing on antiviral drugs and biologics, related therapeutic area.
Weight: 90
One of the world's largest biotechnology firms with large-scale biologics and therapy development.